SCHEMBL214563

SCHEMBL214563

CCC(CC(C)(C)O)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.47
RIPK1 Q13546 2/20 0.40
CCR5 P51681 1/20 0.40
MAPT P10636 1/20 0.40
ALDH1A1 P00352 1/20 0.39
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
TSHR P16473 1/20 0.38
CYP2C19 P33261 1/20 0.38
HKDC1 Q2TB90 1/20 0.38
TRPA1 O75762 1/20 0.38
AOC3 Q16853 1/20 0.37
SLC6A2 P23975 1/20 0.37
SLC6A4 P31645 1/20 0.37
SLC6A3 Q01959 1/20 0.37
NOS3 P29474 1/20 0.37
NOS2 P35228 1/20 0.37
TAAR1 Q96RJ0 2/20 0.36
CYP2D6 P10635 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6238050 0.82 LMNA (0.45) LMNARIPK1CCR5MAPTCYP1A2
SCHEMBL15868611 0.79 MAPT (0.44) LMNARIPK1CCR5MAPTCYP1A2
SCHEMBL2867363 0.79 TRPA1 (0.43) LMNARIPK1CCR5MAPTALDH1A1
SCHEMBL5009479 0.79 RIPK1 (0.45) LMNARIPK1MAPTALDH1A1AOC3
SCHEMBL26341805 0.78 LMNA (0.41) LMNARIPK1CCR5MAPTCYP1A2
SCHEMBL17403420 0.78 CYP1A2 (0.40) LMNARIPK1CCR5MAPTALDH1A1
SCHEMBL169508 0.78 LMNA (0.56) LMNACCR5HKDC1TRPA1AOC3
SCHEMBL21726134 0.78 CCR5 (0.45) LMNARIPK1CCR5MAPTHKDC1
SCHEMBL27254704 0.78 CCR5 (0.45) LMNARIPK1CCR5MAPTHKDC1
SCHEMBL14076957 0.77 LMNA (0.39) LMNARIPK1CCR5MAPTCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8431330-B2 Surface-treating agent for pattern formation and pattern-forming method using the surface-treating agent FUJIFILM CORPORATION (JP) 2013-04-30 US disclosed
US-20120076991-A1 SURFACE-TREATING AGENT FOR PATTERN FORMATION AND PATTERN-FORMING METHOD USING THE SURFACE-TREATING AGENT FUJIFILM CORPORATION (JP) 2012-03-29 US disclosed
US-8088566-B2 Photoresists; using compound containing an orgaooxygen or organosulfur compound FUJIFILM CORPORATION (JP) 2012-01-03 US disclosed
US-20100183978-A1 SURFACE-TREATING AGENT FOR PATTERN FORMATION AND PATTERN FORMING METHOD USING THE TREATING AGENT FUJIFILM CORPORATION (JP) 2010-07-22 US disclosed
EP-2159641-A1 SURFACE TREATMENT AGENT FOR FORMING PATTERN AND PATTERN FORMING METHOD USING THE TREATMENT AGENT Fujifilm Corporation (JP) 2010-03-03 EP disclosed
US-20100028803-A1 SURFACE TREATING AGENT FOR RESIST PATTERN FORMATION, RESIST COMPOSITION, METHOD OF TREATING SURFACE OF RESIST PATTERN THEREWITH AND METHOD OF FORMING RESIST PATTERN FUJIFILM CORPORATION (JP) 2010-02-04 US disclosed
US-20090280440-A1 SURFACE TREATING AGENT FOR RESIST-PATTERN, AND PATTERN-FORMING METHOD USING SAME FUJIFILM CORPORATION (JP) 2009-11-12 US disclosed
US-20080241742-A1 SURFACE-TREATING AGENT FOR PATTERN FORMATION AND PATTERN-FORMING METHOD USING THE SURFACE-TREATING AGENT FUJIFILM CORPORATION (JP) 2008-10-02 US disclosed
EP-1975718-A2 Surface-treating agent for pattern formation and pattern-forming method using the surface-treating agent FUJIFILM Corporation (JP) 2008-10-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080241742-A1 SURFACE-TREATING AGENT FOR PATTERN FORMATION AND PATTERN-FORMING METHOD USING THE SURFACE-TREATING AGENT KRT18, FSCN1, SLC11A2 LMNA 2883/4885RIPK1 2156/4885CCR5 4749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.